75f3c219-419d-4ff0-a5a9-4849293cc7ba.jpeg
8cf53a55-5025-46cb-a443-a0b3cd03724c.jpeg
Interpret this fibroscan report
Reading File
analyse_media
analyse_media
Finding Sources
Finding Sources
Reading File
Reading File
I now have all the information needed to give a thorough interpretation. Here is the full breakdown:
FibroScan Report Interpretation - Pawan Sexena, 46M (18/07/2026)
Report at a Glance
| Parameter | Value | Meaning |
|---|---|---|
| Liver Stiffness (LSM/E) | 7.2 kPa (Median) | Mild-to-moderate fibrosis |
| CAP Score | 293 dB/m (SD: 8) | Moderate-to-severe steatosis |
| IQR/Med Ratio | 13% | Excellent reliability |
| Valid Measurements | 10/10 | Full set acquired |
| Probe | M+ | Standard adult probe |
| Fasting | Yes | Optimal conditions met |
1. Liver Stiffness - 7.2 kPa (Fibrosis Assessment)
The median liver stiffness of 7.2 kPa falls in the mild-to-moderate fibrosis range. Using the VCTE/FibroScan thresholds from Harrison's Principles of Internal Medicine 22E:
- < 6 kPa = Normal liver (no significant fibrosis)
- 6-8 kPa = Mild fibrosis (approximately F1-F2 by METAVIR staging)
- > 8 kPa = Advanced fibrosis (≥F3 concern)
- > 12.5 kPa = Cirrhosis (F4)
7.2 kPa places this patient at the upper end of mild fibrosis / lower boundary of intermediate risk. The MASLD guidelines in Harrison's note that LSM by VCTE < 8 kPa can be used to rule out advanced fibrosis. So advanced fibrosis or cirrhosis is unlikely here - but this is not entirely normal either. It warrants monitoring.
The 10 individual readings were tightly clustered (6.2 to 8.3 kPa), with no major outliers, which supports the reliability of the median value.
2. CAP Score - 293 dB/m (Steatosis / Fatty Liver Assessment)
The CAP of 293 dB/m indicates moderate-to-severe hepatic steatosis (fatty liver). Standard CAP thresholds:
| CAP Range | Steatosis Grade | Approximate % Fat |
|---|---|---|
| < 238 dB/m | S0 (None/minimal) | < 5% |
| 238-259 dB/m | S1 (Mild) | 5-33% |
| 260-289 dB/m | S2 (Moderate) | 34-66% |
| ≥ 290 dB/m | S3 (Severe) | > 66% |
At 293 dB/m, this patient sits at the S2/S3 boundary - moderate to severe steatosis. There is significant fat accumulation in the liver. The SD of only 8 dB/m indicates very consistent CAP readings - this is not a noisy result.
3. Technical Quality - Excellent
- IQR/Med ratio of 13% is well below the 30% threshold for a valid, reliable test. This means the 10 measurements were tightly consistent and the result can be trusted.
- The patient was fasting, which is ideal (eating increases liver stiffness transiently).
- 10/10 valid measurements were obtained - a complete, high-quality exam.
Summary Interpretation
This FibroScan suggests:
-
Significant fatty liver (hepatic steatosis) - The CAP of 293 dB/m is at the severe end of the spectrum. This is the dominant finding. The underlying cause could be metabolic-associated steatotic liver disease (MASLD, formerly NAFLD), alcohol-related fatty liver, or both, and should be correlated with the patient's metabolic profile (BMI, fasting glucose, HbA1c, lipids, alcohol history).
-
Mild fibrosis - The LSM of 7.2 kPa suggests some degree of liver scarring has begun (F1-F2), but there is no evidence of advanced fibrosis or cirrhosis at this stage. Advanced fibrosis is effectively ruled out (threshold >8 kPa for ≥F3; >12.5 kPa for cirrhosis).
-
Good news - The test is technically reliable and the fibrosis score is still in a stage where the condition can be meaningfully reversed or halted with lifestyle modification, metabolic risk factor control, and avoidance of alcohol.
What to Do Next (Typical Clinical Approach)
- Correlate with liver function tests (ALT, AST, GGT, bilirubin, albumin, platelets)
- Calculate FIB-4 score (age, AST, ALT, platelet count) - if FIB-4 < 1.3, low risk; if ≥ 2.67, refer for specialist review
- Screen for metabolic syndrome: fasting glucose/HbA1c, fasting lipid profile, blood pressure, BMI
- Take a detailed alcohol history - even moderate-to-heavy use can independently drive both the steatosis and fibrosis findings
- Lifestyle intervention is the mainstay of treatment at this stage: weight loss (≥5-7% body weight), dietary modification, exercise, and avoidance of alcohol
- Repeat FibroScan in 1-2 years to monitor progression or regression
- Refer to a gastroenterologist/hepatologist if metabolic risk factors are uncontrolled, FIB-4 is elevated, or if there are other concerning features
Note: This interpretation is for informational purposes only. FibroScan results must be interpreted by the treating physician in the context of the full clinical picture, blood tests, and patient history. The report itself carries the same disclaimer.
This is a shared conversation. Sign in to Orris to start your own chat.